Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug

SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks t...

2024-09-09 21:00 1157

MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology

SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneS...

2024-09-09 16:24 1183

MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment tothe United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora P...

2024-09-09 15:00 1061

Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress

* The study involved end-stage oncology patients with no other suitable treatment options. * In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP inhi...

2024-09-09 10:33 1191

Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024

BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...

2024-09-09 08:30 1076

Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024

HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of ...

2024-09-09 02:17 1405

Bc Babycare Marks a Stellar Debut at Germany's Kind+Jugend 2024

COLOGNE, Germany, Sept. 6, 2024 /PRNewswire/ -- Bc Babycare, a leader in innovative products for mothers and babies, made a remarkable debut at Kind+Jugend 2024, the premier international trade fair for baby and toddler outfitting, which opened inCologne, Germany, on September 3. The brand capti...

2024-09-06 23:22 1777

Bc Babycare Marks a Stellar Debut at Germany's Kind+Jugend 2024

Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies

HONG KONG, Sept. 5, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and co...

2024-09-06 08:54 1434

Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement

FORT MILL, S.C., Sept. 5, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ:XFIN

2024-09-06 05:23 2837

A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China

SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval inChina. This groundbreaking achievement is now officially l...

2024-09-05 20:35 1939

A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...

2024-09-05 20:00 2440

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U....

2024-09-05 13:49 1195

Grand launch | Sanyou Bio monkeypox antibody made a great breakthrough

SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyo...

2024-09-05 08:00 1057

LakeShore Biopharma Announces Leadership Transitions

GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-04 20:00 1180

HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial

HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong KongBaptist University (HKBU) has achieved a significant milestone in developing a novel Chinese herbal formulation for ulcerative colitis remission maintenance. Following a submission o...

2024-09-04 15:13 1396

HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guiding treatment decisions in advanced BTC SEOUL, South Korea ,Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, to...

2024-09-03 21:00 1461

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule

SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce...

2024-09-03 20:00 1216

Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa

BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) fo...

2024-09-03 18:00 1063

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" * Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PR...

2024-09-03 15:59 1193

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase2b study for Dercum's disease (CBL-0202 DD Phase2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study i...

2024-09-03 15:18 1189

1 ... 11 12 131415 16 17 ... 214